Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASSIoN trial of intranasal allogeneic mesenchymal stromal cells for neonatal perinatal arterial ischemic stroke
NL-OMON42174Phase 2Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2015
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL) in perinatal arterial ischemic stroke (PAIS) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in lesion size and brain growth and Reorganization of the sensorimotor cortex. Planned start Aug 2015; status: withdrawn.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells (ICSCYL)
03
Conditions
perinatal arterial ischemic stroke (PAIS)
Beyond the preview
Go deeper on NL-OMON42174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42174.